지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2013.12
- 수록면
- 263 - 278 (16page)
이용수
초록· 키워드
오류제보하기
The silkworm extract powder contain 1-deoxynojirimycin (DNJ), a potent α-glycosidase inhibitor, has therapeutic potency against diabetes mellitus. Therefore, natural products containing DNJ from mulberry leaves and silkworm are consumed as health functional food. The present study was performed to evaluate the safety of the silkworm extract powder, a health food which containing the DNJ. The repeated toxicity studies and gentic toxicity studies of the silkworm extract powder were performed to obtain the data for new functional food approval in MFDS. The safety was evaluated by a single-dose oral toxicity study and a 90 day repeated-dose oral toxicity study in Sprague-Dawley rats. The silkworm extract powder was also evaluated for its mutagenic potential in a battery of genetic toxicity test: in vitro bacterial reverse mutation assay, in vitro chromosomal aberration test, and in vivo mouse bone marrow micronucleus assay. The results of the genetic toxicology assays were negative in all of the assays. The approximate lethal dose in single oral dose toxicity study was considered to be higher than 5000 mg/kg in rats. In the 90 day study, the dose levels were wet at 0, 500, 1000, 2000 mg/kg/day, and 10 animals/sex/dose were treated with oral gavage. The parameters that were monitored were clinical signs, body weights, food and water consumptions, ophthalmic examination, urinalysis, hematology, serum biochemistry, necropsy findings, organ weights, and histopathological examination. No adverse effects were observed after the 90 day administration of the silkworm extract powder. The No-Observed-Adverse-Effect-Level (NOAEL) of silkworm extract powder in the 90 day study was 2000 mg/kg/day in both sexes, and no target organ was identified.
목차
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
참고문헌 (26)
참고문헌 신청
Bulletin of the World Health Organization / 2004 / WHO News / Bull. W. H. O 82:635~636
Hughes, A. B. / 1994 / Deoxynojirimycin: synthesis and biological activity / Nat. Prod. Rep. 11:135~162
Yoshikuni, Y. / 1988 / Inhibition of intestinal alpha-glucosidase activity and postprandial hyperglycemia by moranoline and its N-alkyl derivatives / Agric. Biol. Chem. 52:121~128
Yoshikuni, Y. / 1988 / Inhibition of intestinal alpha-glucosidase and postprandial hyperglycemia by N-substituted moranoline derivatives / J. Pharmacobiodyn. 11:356~362
Junge, B. / 1996 / Chemistry and structure activity relationships of glucosidase inhibitors / Handb. Exp. Pharmacol 119:411~482
Hughes, A. B. / 1994 / Deoxynojirimycin: synthesis and biological activity / Nat. Prod. Rep. 11:135~162
Yoshikuni, Y. / 1988 / Inhibition of intestinal alpha-glucosidase activity and postprandial hyperglycemia by moranoline and its N-alkyl derivatives / Agric. Biol. Chem. 52:121~128
Yoshikuni, Y. / 1988 / Inhibition of intestinal alpha-glucosidase and postprandial hyperglycemia by N-substituted moranoline derivatives / J. Pharmacobiodyn. 11:356~362
Junge, B. / 1996 / Chemistry and structure activity relationships of glucosidase inhibitors / Handb. Exp. Pharmacol 119:411~482
이 논문의 저자 정보
최근 본 자료
댓글(0)
0
UCI(KEPA) : I410-ECN-0101-2015-510-001071774